4Q financial markets preview, plus the future of NIH

Plus Novartis CEO’s view of translational science and this week’s Deal in Focus, Flexion-Pacira

On the latest BioCentury This Week podcast, BioCentury’s editors discuss takeaways from the 4Q21 Financial Markets Preview, which zeroed in on how biotech public markets are returning to their pre-pandemic profile of being specialist-driven and whether M&A will finally find its footing. They also discuss Novartis AG (SIX:NOVN; NYSE:NVS) CEO Vasant Narasimhan’s thoughts on new modalities, what’s next for NIH as Director Francis Collins departs and this week’s Deal in Focus, the proposed takeout of  Flexion Therapeutics Inc. (NASDAQ:FLXN) by Pacira BioSciences Inc. (NASDAQ:PCRX).